�Curbing the activity of a pith called "platelet-derived growth factor receptor A" dramatically reduced aggressiveness of an often untreatable childhood muscle cancer in mice and cells, a young study from The University of Texas Health Science Center at San Antonio and partner institutions shows.
Research sites included the UT Health Science Center's Greehey Children's Cancer Research Institute (Greehey CCRI) and the university's departments of Cellular and Structural Biology, Pediatrics, Medicine, and Epidemiology and Biostatistics. National collaborators ar from the University of Virginia, Ohio State University, the Columbus Children's Research Institute, and the Taussig Cancer Center and Lerner Research Institute at the Cleveland Clinic.
The work is reported in the to the highest degree recent online advance take of the journal Oncogene (http://www.nature.com/onc/journal/vaop/ncurrent/abs/onc2008255a.html).
Difficult-to-treat subtype
Childhood muscle cancers, also called rhabdomyosarcomas, ar the most common diffuse tissue sarcomas of puerility. The alveolar subtype is particularly difficult to regale because at diagnosis more than half of the children have lymph node involvement or distant metastasis (spread), the authors wrote.
"The way this disease grows and spreads has perplexed clinicians and researchers for nearly 3 decades, during which clip the dreary outcome for metastatic alveolar rhabdomyosarcoma has remained essentially unchanged despite improvements in surgical technique, radiation delivery and chemotherapy," said coauthor Charles Keller, M.D., help professor of Cellular and Structural Biology at the Greehey CCRI.
The cure rate for the metastatic form is estimated to be 20 pct or let down. Dr. Keller said the findings offer a promising avenue for improving that outcome. "A therapeutic scheme for children with musculus cancer power be developed that would target this growth receptor and perhaps similar ones at the same fourth dimension," he aforesaid. "The benefit to the patient is that such treatments ar clinically available today for adult cancer patients wHO have other diseases. Importantly, too, the way these targeted therapies work is less toxic than chemotherapy."
Authentic model
The researchers studied genetically engineered mice with tumors that develop the mutations, and haunt metastases, inherent to alveolar rhabdomyosarcomas. Dr. Keller developed this specialized mouse neoplasm model spell training in the science lab of 2007 Nobel Laureate Mario Capecchi, Ph.D., at the University of Utah.
In the current study, assays performed in the Keller laboratory by postdoctoral trainee Eri Taniguchi, Ph.D., showed that platelet-derived growth factor receptor A, and deuce proteins that mediate its effects, were highly activated in both the elementary and metastatic tumors.
Using trey different methods to dampen the platelet-derived growth factor receptor, the scientists celebrated significant simplification of neoplasm cell outgrowth both in the mice and in cell cultures.
"We believe this clearly establishes platelet-derived maturation factor sensory receptor A as a voltage future therapeutic target in alveolar rhabdomyosarcoma," Dr. Keller said.
NCI ulysses S. Grant support
This work is supported by a five year, $1.5 million duncan Grant recently awarded by the National Cancer Institute (NCI) to the Keller testing ground, and it is likewise the base for the Greehey CCRI's forthcoming rank in the NCI's Pediatric Preclinical Testing Program. Dr. Keller volition lead the Greehey CCRI Pediatric Preclinical Testing Initiative.
One tempering gene in the study is this determination: while two-thirds of the mice showed a response, one-third developed resistance to the therapy after two weeks. This mimics opposition rates seen with adult cancers treated with a receptor inhibitor. Ongoing studies at the Greehey CCRI now direct to watch how resistance can be overcome. "Moving our results to the clinic will require close attention and further study of how tumors become resistant to this drug," Dr. Keller said.
Co-authors from the UT Health Science Center are the trail author, Dr. Taniguchi; Koichi Nishijo, M.D., Ph.D., and Amanda T. McCleish, all at the Greehey CCRI; Joel E. Michalek, Ph.D., departments of Epidemiology and Biostatistics and Pediatrics; Marcia H. Grayson and Anthony J. Infante, M.D., Ph.D., Pediatrics; and Hanna E. Abboud, M.D., the Jay Stein Professor in Medicine/Nephrology.
Dr. Keller and other staff at the Greehey CCRI are members of the Cancer Therapy & Research Center at the UT Health Science Center.
About the UT Health Science Center San Antonio
The University of Texas Health Science Center at San Antonio is the starring research institution in South Texas and one of the major health sciences universities in the universe. With an operating budget of $576 million, the Health Science Center is the tribal chief catalyst for the $15.3 one thousand million biosciences and health guardianship sector in San Antonio's economy. The Health Science Center has had an estimated $35 billion shock on the region since inception and has expanded to sextet campuses in San Antonio, Laredo, Harlingen and Edinburg. More than 23,000 graduates (physicians, dentists, nurses, scientists and allied health professionals) serve in their fields, including many in Texas. Health Science Center faculty ar international leadership in crab, cardiovascular disease, diabetes, ripening, stroke prevention, kidney disease, orthopaedics, inquiry imaging, graft surgery, psychological medicine and clinical neurosciences, hurting management, genetic science, nursing, allied health, dental medicine and many other fields. For more information, inspect http://www.uthscsa.edu.
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Dr.
San Antonio, TX 78229-3900
United States
http://www.uthscsa.edu
More info
